Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Jun;24(6):780-1; author reply 782.
doi: 10.1007/s11606-009-0957-1.

Gabapentin versus tricyclics for neuropathic pain

Alec B O'Connor
Comparative Study

Gabapentin versus tricyclics for neuropathic pain

Alec B O'Connor. J Gen Intern Med. 2009 Jun.
No abstract available

PubMed Disclaimer

Comment on

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/s11606-008-0877-5', 'is_inner': False, 'url': 'https://doi.org/10.1007/s11606-008-0877-5'}, {'type': 'PMC', 'value': 'PMC2628998', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2628998/'}, {'type': 'PubMed', 'value': '19089502', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/19089502/'}]}
    2. Chou R, Carson S, Chan BKS. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials. J Gen Intern Med. 2009;24:178–88. - PMC - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0885-3924(00)00181-0', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0885-3924(00)00181-0'}, {'type': 'PubMed', 'value': '11027910', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/11027910/'}]}
    2. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage. 2000;20:280–5. - PubMed
    1. Chow SC, Liu JP. Randomization and blinding. In Design and Analysis of Clinical Trials. Hoboken, New Jersey: John Wiley & Sons, Inc.; 2004.
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1371/journal.pmed.0030425', 'is_inner': False, 'url': 'https://doi.org/10.1371/journal.pmed.0030425'}, {'type': 'PMC', 'value': 'PMC1626553', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC1626553/'}, {'type': 'PubMed', 'value': '17076559', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/17076559/'}]}
    2. Boutron I, Estellat C, Guittet L, et al. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatment: a systematic review. PLoS Med. 2006;3:1931–9. - PMC - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '16908919', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16908919/'}]}
    2. Steinman MA, Bero LA, Chren MM, Landefield CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006;145:284–93. - PubMed

MeSH terms